10.1007/BF00401145 7
[DOI] [PubMed] [Google Scholar] 61.von Loeffelholz C., Birkenfeld A.L
Injectable forms deliver medication directly into the bloodstream or tissue, bypassing digestive absorption variability and sometimes producing more predictable side effect patterns
Nevertheless, unimolecular GIPGLP-1 co-agonism is an effective therapy for type 2 diabetes, associated with weight loss and reduction of fat mass, in rats, mice, monkeys and humans [66]
It does not mean the medication causes the warned condition in humans
n = 15) and were assessed at 4 and 12 weeks for isometric leg strength, functional performance, body composition, diet, quality of life, and depressive symptoms